-
Hillstream BioPharma Announces Pricing of Initial Public Offering
Hillstream BioPharma Announces Pricing of Initial Public Offering January 11th, 2022 BRIDGEWATER, NJ / ACCESSWIRE / January 11, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic…January 11, 2022 -
Hillstream Selected to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. Wainwright
Hillstream Selected to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. Wainwright January 11th, 2021 Bridgewater, New Jersey - Hillstream BioPharma, Inc. (“Hillstream”), a clinical- stage biotechnology company leveraging its…January 11, 2021 -
Hillstream BioPharma’s HSB-888 Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Osteosarcoma
Hillstream BioPharma’s HSB-888 Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Osteosarcoma November 23rd, 2020 Osteosarcoma remains the most common primary pediatric bone malignancy mostly occurring in adolescents for which…November 23, 2020 -
Hillstream BioPharma Announces Richard M. Stone, MD as New Member to Scientific Advisory Board
Hillstream BioPharma Announces Richard M. Stone, MD as New Member to Scientific Advisory Board November 18th, 2020 Hillstream BioPharma Announces Richard M. Stone, MD as New Member to Scientific Advisory Board Expertise…November 18, 2020 -
Hillstream BioPharma Announces Renewal of CRADA with National Center for Advancing Translational Sciences for Use of Quatramer™ Technology with HDAC6-PI3Kδ Dual Inhibitor for AML
Hillstream BioPharma Announces Renewal of CRADA with National Center for Advancing Translational Sciences for Use of Quatramer™ Technology with HDAC6-PI3Kδ Dual Inhibitor for AML November 2nd, 2020 Hillstream BioPharma Announces Renewal of…November 2, 2020 -
Hillstream BioPharma to Participate in Panel During 2020 NORD Rare Diseases and Orphan Products Breakthrough Summit 2020
Hillstream BioPharma Completes Pre-IND Review with FDA on HSB-1216 for Small Cell Lung Cancer (SCLC) October 1st, 2020 Bridgewater, New Jersey, October 21, 2020 – Hillstream BioPharma Inc. (“Hillstream”, the “Company”), a…October 21, 2020 -
Hillstream BioPharma to Participate in Panel During 2020 NORD Rare Diseases and Orphan Products Breakthrough Summit 2020
HillstreaHillstream BioPharma to Participate in Panel During 2020 NORD Rare Diseases and Orphan Products Breakthrough Summit 2020 October 1st, 2020 Hillstream BioPharma to Participate in Panel During 2020 NORD Rare Diseases and…October 5, 2020 -
Hillstream BioPharma to Present at the Tenth Annual BioNJ BioPartnering Virtual Conference
Hillstream BioPharma to Present at the Tenth Annual BioNJ BioPartnering Virtual Conference October 1st, 2020 Hillstream BioPharma to Present at the Tenth Annual BioNJ BioPartnering Virtual Conference Bridgewater, New Jersey, October 1,…October 1, 2020 -
Hillstream BioPharma to Present at the World Orphan Drug Conference USA 2020
Hillstream BioPharma to Present at the World Orphan Drug Conference USA 2020 August 17th, 2020 Hillstream BioPharma to Present at the World Orphan Drug Conference USA 2020 Chester, New Jersey, August 17,…August 17, 2020 -
Hillstream BioPharma Presentations at 2020 AACR Virtual Annual Meeting II
Hillstream BioPharma Presentations at 2020 AACR Virtual Annual Meeting II FEBRUARY 10, 2020 Abstracts highlight data from HSB-1216 (Salinomycin QUATRAMER™) in small cell lung cancer and triple negative breast cancer Chester, NJ…May 19, 2020
Loading posts...
Recent Posts
- Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215
- Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics
- Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers
- Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson
- Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule